Corvus reveals $33.5M series A round

Immuno-oncology play Corvus Pharmaceuticals Inc. (Burlingame, Calif.) disclosed that it raised $33.5 million in a series A round in December 2014. OrbiMed Advisors led the round, and Novo Ventures and Adams Street Partners also participated.

Corvus' management team includes several executives from Pharmacyclics Inc. Its CEO, Richard Miller, and CFO, Leiv Lea, held the same titles at Pharmacyclics. AbbVie Inc. (NYSE:ABBV) completed its $21 billion acquisition of Pharmacyclics in May. ...